BIOA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Bioage Labs's net margin of --. Bioage Labs's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Bioage Labs has a consensus price target of $6.75, signalling upside risk potential of 96.79%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 673.81%. Given that Perspective Therapeutics has higher upside potential than Bioage Labs, analysts believe Perspective Therapeutics is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Bioage Labs's net income of -$13.6M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Bioage Labs's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 12.04x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Bioage Labs's net margin of 12.11%. Bioage Labs's return on equity of -- beat Electromed's return on equity of 15.91%.

Bioage Labs has a consensus price target of $6.75, signalling upside risk potential of 96.79%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 63.79%. Given that Bioage Labs has higher upside potential than Electromed, analysts believe Bioage Labs is more attractive than Electromed.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Bioage Labs's net income of -$13.6M is lower than Electromed's net income of $2M. Notably, Bioage Labs's price-to-earnings ratio is -- while Electromed's PE ratio is 30.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 3.39x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Bioage Labs's net margin of 24.22%. Bioage Labs's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Bioage Labs has a consensus price target of $6.75, signalling upside risk potential of 96.79%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $903.59 which suggests that it could grow by 65.37%. Given that Bioage Labs has higher upside potential than Regeneron Pharmaceuticals, analysts believe Bioage Labs is more attractive than Regeneron Pharmaceuticals.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Bioage Labs pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Bioage Labs's net income of -$13.6M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Bioage Labs's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 4.43x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Reshape Lifesciences has a net margin of -- compared to Bioage Labs's net margin of -68.98%. Bioage Labs's return on equity of -- beat Reshape Lifesciences's return on equity of -187.93%.

Bioage Labs has a consensus price target of $6.75, signalling upside risk potential of 96.79%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 10136.49%. Given that Reshape Lifesciences has higher upside potential than Bioage Labs, analysts believe Reshape Lifesciences is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.592, suggesting its more volatile than the S&P 500 by 59.165%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Reshape Lifesciences quarterly revenues of $2.3M. Bioage Labs's net income of -$13.6M is lower than Reshape Lifesciences's net income of -$1.6M. Notably, Bioage Labs's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.04x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.